AIM: Arbidol is an immunomodulator that was first developed in Russia. In this study, we report the antiviral activity of arbidol against Hantaan virus (HTNV) in vitro and in vivo. METHODS: The antiviral activity of arbidol in vitro was determined by plaque-forming assay, ranging from 0.5 to 8 microg/mL. To investigate whether arbidol has an antiviral effect in vivo, suckling BALB/c mice infected with HTNV were treated with arbidol at 24 h before infection with a 5, 10 or 20 mg.kg(-1).d(-1), once per day, for 10 days. On day 12 and 28 post infection (pi), histopathological changes and viral antigen were detected. On days 4, 8, 12, and 16 pi, the viral load of target organs and serum TNF-alpha levels of arbidol-treated animals were determined. RESULTS: Arbidol was found to have potent inhibitory activity against HTNV when added in vitro before or after viral infection, with a 50% inhibitory concentration (IC(50)) of 0.9 and 1.2 microg/mL, respectively. The 50% lethal dose (LD(50)) of arbidol for suckling mice was 78.42 mg.kg(-1).d(-1). Oral administration of arbidol increased both survival rate and mean time to death (MTD). Treatment with arbidol reduced histopathological changes, decreased viral load and viral antigen levels, and modulated the level of serum TNF-alpha. CONCLUSION: Arbidol has the ability to elicit protective antiviral activity against HTNV in vivo and in vitro.Acta Pharmacologica Sinica (2009) 30: 1015-1024; doi: 10.1038/aps.2009.53; published online 8 June 2009.
AIM: Arbidol is an immunomodulator that was first developed in Russia. In this study, we report the antiviral activity of arbidol against Hantaan virus (HTNV) in vitro and in vivo. METHODS: The antiviral activity of arbidol in vitro was determined by plaque-forming assay, ranging from 0.5 to 8 microg/mL. To investigate whether arbidol has an antiviral effect in vivo, suckling BALB/c mice infected with HTNV were treated with arbidol at 24 h before infection with a 5, 10 or 20 mg.kg(-1).d(-1), once per day, for 10 days. On day 12 and 28 post infection (pi), histopathological changes and viral antigen were detected. On days 4, 8, 12, and 16 pi, the viral load of target organs and serum TNF-alpha levels of arbidol-treated animals were determined. RESULTS:Arbidol was found to have potent inhibitory activity against HTNV when added in vitro before or after viral infection, with a 50% inhibitory concentration (IC(50)) of 0.9 and 1.2 microg/mL, respectively. The 50% lethal dose (LD(50)) of arbidol for suckling mice was 78.42 mg.kg(-1).d(-1). Oral administration of arbidol increased both survival rate and mean time to death (MTD). Treatment with arbidol reduced histopathological changes, decreased viral load and viral antigen levels, and modulated the level of serum TNF-alpha. CONCLUSION:Arbidol has the ability to elicit protective antiviral activity against HTNV in vivo and in vitro.Acta Pharmacologica Sinica (2009) 30: 1015-1024; doi: 10.1038/aps.2009.53; published online 8 June 2009.
Authors: T Yamanouchi; K Domae; O Tanishita; Y Takahashi; K Yamanishi; M Takahashi; T Kurata Journal: Microbiol Immunol Date: 1984 Impact factor: 1.955
Authors: Lisa Oestereich; Toni Rieger; Melanie Neumann; Christian Bernreuther; Maria Lehmann; Susanne Krasemann; Stephanie Wurr; Petra Emmerich; Xavier de Lamballerie; Stephan Ölschläger; Stephan Günther Journal: PLoS Negl Trop Dis Date: 2014-05-01
Authors: Casey C Perley; Rebecca L Brocato; Steven A Kwilas; Sharon Daye; Alicia Moreau; Donald K Nichols; Kelly S Wetzel; Joshua Shamblin; Jay W Hooper Journal: PLoS One Date: 2019-05-10 Impact factor: 3.240
Authors: Susan L Fink; Lucia Vojtech; Jessica Wagoner; Natalie S J Slivinski; Konner J Jackson; Ruofan Wang; Sudip Khadka; Priya Luthra; Christopher F Basler; Stephen J Polyak Journal: Sci Rep Date: 2018-06-12 Impact factor: 4.379
Authors: Jan Haviernik; Michal Štefánik; Martina Fojtíková; Sabrina Kali; Noël Tordo; Ivo Rudolf; Zdeněk Hubálek; Luděk Eyer; Daniel Ruzek Journal: Viruses Date: 2018-04-10 Impact factor: 5.048